Sangamo Therapeutics Inc. (SGMO) announced that its common stock will be delisted from the Nasdaq Capital Market on May 5 2026 and will begin trading on the OTCQB Venture Market under the same ticker. The delisting follows a Nasdaq notice that SGMO failed to meet the exchange’s minimum bid‑price requirement, a regulatory action that signals significant liquidity and financial distress for the company.
Sangamo’s financial position underscores the severity of the situation. For the full year 2025, the company reported revenue of $39.6 million, down from $57.8 million in 2024, and a net loss of $122.9 million, or $0.44 per share. Cash and cash equivalents stood at $20.9 million as of December 31 2025, providing a runway into the third quarter of 2026. Shareholder equity was negative $14.3 million, and the company had no debt, leaving it vulnerable to a liquidity crunch if additional capital is not secured.
Management has highlighted that the company’s pipeline remains a key driver of future value. CEO Sandy Macrae noted that progress in the Fabry disease gene‑therapy program, including a rolling BLA submission for ST‑920, is contingent on securing additional funding and a commercialization partner. The company also continues to pursue a Phase 1/2 study in small‑fiber neuropathy and has entered into capsid‑licensing agreements with Eli Lilly and Astellas, generating non‑dilutive revenue streams that could extend the cash runway if milestones are met.
SGMO had previously been granted a compliance extension by Nasdaq until April 27 2026, but the company failed to regain the required bid price by that deadline. The company has indicated it will request a hearing to appeal the delisting decision, a process that typically involves a review of the company’s financials and a determination of whether it can meet the exchange’s standards within a specified timeframe.
In addition to the delisting, Sangamo is actively pursuing capital‑raising options and a strategic partnership for its Fabry disease program. The February 2026 underwritten offering of $25 million provided a temporary boost, but the company’s cash reserves are projected to be exhausted by the end of Q3 2026 unless new financing or a partnership materializes. The search for a Fabry commercialization partner remains a priority, as it would provide both upfront and milestone payments that could stabilize the company’s financial position.
The transition to OTCQB will reduce liquidity and visibility for investors, potentially limiting the company’s ability to raise capital in the future. The delisting also raises the risk of bankruptcy, as the company has warned that it may need to liquidate assets or seek protection under the U.S. Bankruptcy Code in the near term. Investors and stakeholders will closely monitor the company’s appeal outcome, capital‑raising progress, and partnership negotiations to assess the likelihood of a turnaround.
Overall, the delisting marks a significant setback for Sangamo Therapeutics, highlighting the urgent need for a substantial partnership or financing to avoid further regulatory and market consequences. The event underscores the company’s precarious financial footing and the critical importance of securing a viable commercialization strategy for its gene‑therapy pipeline.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.